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Defining the precise molecular strategies
that coordinate patterns of transcriptional
responses to specific signals is central for
understanding normal development and
homeostasis as well as the pathogenesis
of hormone-dependent cancers. Here we
report specific prostate cancer cell/macro-
phage interactions that mediate a switch
in function of selective androgen receptor
antagonists/modulators (SARMs) from re-
pression to activation in vivo. This is based
on an evolutionarily conserved receptor N-
terminal L/HX7LL motif, selectively present
in sexsteroid receptors, that causes recruit-
ment of TAB2 as a component of an N-CoR
corepressor complex. TAB2 acts as a sen-
sor for inflammatory signals by serving
as a molecular beacon for recruitment of
MEKK1, which in turn mediates dismissal
of the N-CoR/HDAC complex and permits
derepression of androgen and estrogen re-
ceptor target genes. Surprisingly, this con-
served sensor strategy may have arisen to
mediate reversal of sex steroid-dependent
repression of a limited cohort of target
genes in response to inflammatory signals,
linking inflammatory and nuclear receptorligand responses to essential reproductive
functions.
INTRODUCTION
The pattern of transcriptional response to the multiple signal-
ing factors impacting each cell reflects, in part, an ability to
integrate these inputs into a coordinated program of gene
activation and repression. The actions of nuclear receptors
have provided an ideal model in which to investigate this
question, as androgen and estrogen receptors can bind
both to agonists, such as dihydrotestosterone (DHT) and
17-b-estradiol (E2), or to selective androgen and estrogen re-
ceptor modulators (SARMs, SERMs), which act as antago-
nists or as weak agonists in a context-dependent fashion.
Androgens, acting via androgen receptor (AR), are essen-
tial for normal growth and function of the prostate gland and
in all animal models of prostate carcinogenesis. While andro-
gen ablation is a standard treatment for prostate cancer
(Feldman and Feldman, 2001; reviewed inDebes and Tindall,
2004), there is an invariant progression from androgen-
dependent to androgen-independent growth, even though
high levels of AR generally persist (Feldman and Feldman,
2001; Chen et al., 2004; reviewed in Debes and Tindall,
2004). Resistance to antiandrogen treatment has been pos-
tulated to reflect diversemechanisms such as changes of AR
expression and functions (silencing of the AR gene, muta-
tions in the AR sequence, and increased levels of AR), alter-
ations of levels of nuclear receptor cofactors, activation of
growth factor or kinasepathways, and decreased expression
of tumor suppressors or increased expression of antiapop-
totic genes (Feldman and Feldman, 2001; Chen et al.,
2004; reviewed in Debes and Tindall, 2004); but each ofCell 124, 615–629, February 10, 2006 ª2006 Elsevier Inc. 615
these could only account for a subset of resistance events.
Analogous to other members of the nuclear receptor super-
family, AR actions require AF-2 transcription-activation func-
tion and an extended N-terminal domain with a strong AF-1
function (Onate et al., 1998; Bevan et al., 1999). Agonists
and antagonists induce different conformations of helix 12,
with antagonists blockingAF-2 function by preventing forma-
tion of an effective ‘‘charge clamp’’ for the LXXLL interaction
motif (Darimont et al., 1998; Nolte et al., 1998; Shiau et al.,
1998).
Investigation of active repression of gene expression by
unliganded nuclear receptors has led to the identification of
the nuclear receptor corepressors, N-CoR (Ho¨rlein et al.,
1995) and SMRT (Chen and Evans, 1995; Sande and Prival-
sky, 1996), which contain multiple repressor domains that
could transfer their active repression function, recruiting his-
tone deacetylases (HDACs). Based on genetic analyses,
N-CoR proves to be required for the inhibitory function
of estrogen receptor (ER) antagonists (SERMs) (Jackson
et al., 1997; Smith et al., 1997; Lavinsky et al., 1998; re-
viewed in Glass and Rosenfeld, 2000; McKenna and
O’Malley, 2002). N-CoR has been found as a component
of many complexes, including TBL1/TBLR1/HDAC3/GPS2
(Guenther et al., 2000; Li et al., 2000; Wen et al., 2000;
Zhang et al., 2002; Yoon et al., 2003), TAB2/HDAC3 (Baek
et al., 2002), Sin3/HDAC1, 2 complexes (Alland et al.,
1997; Heinzel et al., 1997; Nagy et al., 1997), complexes
containing SWI/SNF-related proteins (Underhill et al., 2000),
andmultiple other complexes (reviewed in Jepsen andRose-
nfeld, 2002). Sequences referred to as the CoRNR box (Hu
and Lazar, 1999) or alternatively as LXX I/H I XXX I/L motifs
(Nagy et al., 1999; Perissi et al., 1999), appear to bind in
the hydrophobic pocket that is occupied by the coactivator
LXXLL helical motifs upon binding of ligand.
Recently, it has been recognized that there is an increased
monocyte/macrophage infiltration in the adipose tissue of
obese individuals and that these macrophages may be a
major localized source of the inflammatory cytokines that
are linked to insulin resistance (Weisberg et al., 2003; Xu
et al., 2003). Among their phenotypic actions, proinflamma-
tory signals can derepress genes regulated by the p50 ho-
modimer of NF-kB DNA binding factors by dismissal of the
N-CoR complex (Baek et al., 2002), influencing the behavior
of prostate cancer cells in vitro (Kim et al., 2005). Based on
analysis of IKKb gene-deleted mice, interruption of the IKK/
NF-kB pathway attenuates inflammation-associated tumors
(Greten et al., 2004). It is thus of particular interest to deter-
mine whether a macrophage/prostate cancer cell interaction
occurs if it is a common event in prostate cancer and
whether this serves to elicit inflammatory signals capable of
impacting the therapeutic effectiveness of SARMs. These
compounds typically function initially as antagonists in vivo
but almost invariably become ineffective over a period of
time (Feldman and Feldman, 2001; Chen et al., 2004; re-
viewed in Debes and Tindall, 2004).
In this manuscript, we establish that specific interactions
between prostate cancer cells and macrophages appear to
occur in most prostate cancers examined and convert616 Cell 124, 615–629, February 10, 2006 ª2006 Elsevier Inc.SARMs to function as agonists by activating a functional pro-
gramof specific proinflammatory signals that causedismissal
of the N-CoR holocorepressor complex from AR. This
derepression effect requires TAB2 (Takaesu et al., 2000), re-
cruited to steroid hormone receptors through a specific, evo-
lutionarily conserved, N-terminal L/HX7LL motif found in sex
steroid receptors but not in other nuclear receptors. This
motif serves as adiscriminatorymolecular beacon for specific
proinflammatory cytokine signals, modulating a coordinated
program of gene derepression. One evolutionary basis for
this signal processing module appears to be the importance
of inflammatory signal-dependent derepression of a cohort of
sex steroid-repressed genes in reproductive biology.
RESULTS
Macrophage/Prostate Cancer Cell Interaction
Causes Resistance to SARMs
To examine potential direct interactions between macro-
phages and prostate cell lines, we initially used RWPE1-
transformed prostate cells and fluorescein-labeled THP-1
monocytes/macrophages and found a specific RWPE1/
macrophage interaction (Figure 1A). Pretreatment of RWPE1
cells with TNFa, LPS, or IL-1 induced the expression of
VCAM-1 (data not shown) and enhanced the engagement
of macrophages (Figures 1A and 1B). We found that these
interactions were blocked by addition of a specific VCAM-1
monoclonal IgG (Figures 1A and 1B). These data raised the
possibility that such interactions might also operate in vivo
in prostate cancer.We therefore examined tissue arrays con-
taining patient-matched sections with both normal and can-
cer-containing regions of prostates, stained for CD68, a spe-
cific marker of macrophages. This revealed that virtually
100%of the tumor samples exhibitedmacrophage infiltration
aswell as stromal interactionswithmacrophages (Figure 1C).
There wasmuch less interaction between macrophages and
histologically ‘‘normal’’ cellular areas in the resected tumors
(Figures 1C and 1D).
Therefore, we considered that macrophage/prostate can-
cer cell interactions might represent a possible in vivo mech-
anism involved in SARM resistance in prostate cancer. We
explored whether the direct cell-to-cell interactions that we
observed between macrophages and prostate cancer cells
might cause changes in the activity of SARMs based on
macrophage activation and release of proinflammatory cyto-
kines. Nuclear microinjection studies were performed in
RWPE1 cells pretreated with TNFa, where indicated, using
a prostate-specific antigen (PSA) promoter-controlled re-
porter. Following microinjection of the PSA reporter, THP-1
cells were added to the prostate cells for 6 hr and then either
DHT or bicalutamide was added for 6 hr. We observed the
expected activity of the PSA reporter whether or not the cells
had been pretreated with TNFa (Figure 1E), with a robust
increase in activity after DHT, but not bicalutamide (Fig-
ure 1E). Addition of macrophages to untreated RWPE-1 cells
clearly increased the basal activity, although less than TNFa-
pretreated cells, due probably to lesser adhesion of macro-
phages to prostate cells (Figure 1A). In TNFa-pretreated
Figure 1. Macrophage-Prostate Cell Interaction Converts an AR Antagonist to an Agonist
(A) Interaction between fluorescein-labeled THP-1monocyte/macrophages (green) and RWPE1 transformed prostate cells upon stimulations. DAPI staining
(blue) indicates the cell nuclei.
(B) Quantitative analysis of relative fluorescence that represents the amount of macrophages engaged to prostate cells in (A). One representative of three
independent experiments is shown.
(C) Tissue microarrays (A302) from prostate cancer patients were stained with macrophage-specific marker CD68. Representatives of cancer tissues and
patient-matched pathologically benign tissues are shown. CD68+ cells appear in dark red. Higher magnification shows a specific macrophage-cancer cell
interaction.
(D) Quantitative evaluation of infiltrating macrophages in prostate tissues of 32 patients. P value was calculated by Student’s t test.
(E) Effects of macrophage/prostate cell interaction on AR antagonist. RWPE1 and LNCaP cells were single-cell microinjected with lacZ reporters driven by
the PSA and KLK2 promoters, respectively. After being incubated with THP-1monocyte/macrophages and neutralizing antibodies against human VCAM-1
(aVCAM-1) where indicated, RWPE1 or LNCaP cells were treated with ligands and/or blocking reagents (IL-1ra: human IL-1 receptor antagonist; aIL-1RI:
neutralizing antibodies against human IL-1 receptor type I). Data are represented as mean ± SEM.RWPE1 cells cocultured with macrophages, there was an
agonist-like induction of reporter activity in the presence of
bicalutamide, which was reversed by the addition of
VCAM-1 antibody prior to macrophage addition (Figure 1E).
We observed similar effects using the promoter of anotherAR target gene, KLK2, in LNCaP cells (Figure 1E). To further
test the role of IL-1b, one of the major cytokines secreted by
macrophages that derepresses p50-dependent genes (e.g.,
KAI1), we blocked IL-1 signaling by adding IL-1 receptor an-
tagonist (IL-1ra) or neutralizing antibodies to type I IL-1Cell 124, 615–629, February 10, 2006 ª2006 Elsevier Inc. 617
Figure 2. N-CoR Corepressors in AR
Antagonist Actions
(A) Single-cell nuclear microinjection of aN-CoR
IgG largely relieved the bicalutamide-dependent
repression of an ARE-lacZ reporter.
(B) In N-CoR/ MEFs, bicalutamide acted as an
agonist.
(C) Microinjection of N-CoR siRNA resulted in
a switch from repression to activation.
(D) Chromatin immunoprecipitation (ChIP) assay
of AR occupancy on the PSA promoter in re-
sponse to hormone treatment in LNCaP cells (bi-
calutamide: 10 mM; DHT: 100 nM for 1 hr).
(E) Serial 2-step ChIP assay to determine whether
the different corepressor complexes are assem-
bled on the same promoter. Soluble chromatin
from LNCaP cells (treated for 1 hr with bicaluta-
mide or CPA for samples using aTBLR1, aBrg-1,
and aN-CoR in the 2nd ChIP) was first immuno-
precipitated with indicated antibodies (1st IP) and
reimmunoprecipitated with antibodies as shown
(2nd IP).
(F) Microinjection of IgGs against HDAC1,
HDAC2, or HDAC3 fully relieved the repression
by CPA bound AR.
(G) In response to bicalutamide, HDAC1 and
HDAC3, though not HDAC2, were required for
repression. Data are represented as mean ±
SEM.receptor (a-IL-1RI) (Figure S1) into the medium after micro-
injection of reporters. Under those conditions, the macro-
phage-induced agonistic activity of bicalutamide was effi-
ciently abrogated (Figure 1E), suggesting an important role
of IL-1 signaling in resistance to SARMs.
IL-1b Converts Androgen Antagonists to Function
as Agonists
Because IL-1b blocks the activity of corepressors including
N-CoR (Baek et al., 2002), we then conducted mechanistic
studies to investigate the role of N-CoR and other repres-
sors in SARM-dependent transcriptional repression. Sin-
gle-cell nuclear microinjection of specific a-N-CoR IgG
abolished the repression of a reporter under control of an
AR response element in the presence of bicalutamide (Fig-618 Cell 124, 615–629, February 10, 2006 ª2006 Elsevier Inc.ure 2A). AR antagonists behaved as agonists in MEFs from
N-CoR/ mice, stimulating reporter gene expression (Fig-
ure 2B). These results were validated using siRNAs against
N-CoR (Perissi et al., 2004), which reversed bicalutamide-
dependent repression function (Figure 2C), consistent with
the finding that failure of N-CoR recruitment occurs in
aggressive tumors with AR overexpression and antagonist
resistance (Chen et al., 2004). To a lesser extent, SMRT was
also required for SARM-dependent repression (data not
shown).
We observed the presence of individual components of
many distinct N-CoR complexes on the PSA promoter
(Cleutjens et al., 1996) in bicalutamide-treated cells using
chromatin immunoprecipitation (ChIP) assay (Figure 2D), but
it was unclear whether these complexes are independently
recruited as distinct N-CoR complexes or combinatorially re-
cruited as a holocomplex (Shang et al., 2002). Sequential
ChIP assay of the PSA promoter revealed that many compo-
nents that mark the independently isolated N-CoR complex,
including the TAB2/HDAC3-, the TBL1/TBLR1-, the Sin3-,
and the Brg1-containing complexes, were apparently co-
recruited in bicalutamide-dependent repression (Figure 2E).
In contrast, an MBD3-containing complex (Zhang et al.,
1999)may not be simultaneously assembledwith other com-
ponents, such as the Sin3 complex, on the PSA promoter
(Figure 2E).
Injection of specific purified IgGs against HDAC1, 2, or 3
showed that blocking the actions of any of these HDACs re-
lieved cyproterone (CPA)-dependent repression, while
HDAC1 and 3, but not HDAC2, were required for bicaluta-
mide-mediated repression (Figures 2F and 2G). Because
HDACs that lack functional HDAC activity failed to rescue
the knockdown effects of each HDAC siRNA in the presence
of bicalutamide or CPA (Figures S2A, S2B, and S2C) and
functional HDAC2 and HDAC3 failed to compensate for
the loss of HDAC1 activity (Figure S2D), distinct HDAC enzy-
matic activities are suggested to be combinatorially required
for maintenance of the antagonistic effects of SARMs on AR.
Recombinant IL-1b ‘‘switched’’ bicalutamide or CPA to
function as an agonist, and this switch could be overcome
by overexpression of N-CoR (Figure 3A). Upon stimulation
by IL-1b, there was a progressive and complete dismissal
of all components of the N-CoR-containing complex re-
cruited by SARM bound AR for the PSA promoter assessed
using ChIP assay (Figure 3B). N-CoR was detected in both
nuclear and cytoplasmic locations in either nontreated or
SARM-treated LNCaP prostate cancer cells but became
more preferentially localized to cytoplasm after IL-1b treat-
ment (Figure 3C). Consistent with the observation that TAB2
is a substrate for MEKK1, potentially causing the exposure of
a nuclear export signal (Baek et al., 2002), IL-1b-dependent
loss of the N-CoR complex from AR was accompanied by
a transient recruitment of MEKK1 (Figure 3B). Intriguingly,
MEKK1 remained transiently associated with the promoter
after dismissal of TAB2, which may reflect subsequent
MEKK1/coactivator interactions, as MEKK1/Tip60 interac-
tions can be detected by coimmunoprecipitation analysis
(Figure S3A). Injection of either aTAB2 or aMEKK1 IgG abol-
ished the activation of an androgen-dependent reporter in
the presence of IL-1b and SARM (Figure 3D). Similarly,
IL-1b-dependent agonistic activity of SARMs was abolished
using MEFs either from MEKK1 gene-deleted mice (Fig-
ure 3E) or from TAB2 gene-deleted mice (Figure 3F), sup-
porting the model that MEKK1 recruitment to TAB2 is
required for the removal of N-CoR complexes and derepres-
sion of AR target genes. In TAB2/ MEFs, the SARM bica-
lutamide acted as an antagonist even with IL-1b treatment
unless TAB2 was reexpressed or N-CoR/SMRT expression
was abrogated by microinjection of specific siRNAs (Fig-
ure 3G). In MEKK1/ MEFs, we rescued SARM bound
AR activation by IL-1b by expression of wild-type MEKK1
or a MEKK1 protein with a point mutation to block its internal
ubiquitin ligase activity (C478A) (Lu et al., 2002). MEKK1 har-boring a mutation blocking its protein kinase activity
(D1369A) failed to function in AR derepression (Figure 3H).
An RNA-profiling experiment revealed that almost all DHT-
stimulated gene transcripts recorded were also induced by
bicalutamide in the presence of IL-1b, suggesting that this
strategy regulates most or all AR-dependent genes (Fig-
ure 4A, Table S1).
Molecular Mechanisms of Steroid Hormone
Receptor-Specific Derepression by IL-1b
Analogous to events on SARM bound AR, IL-1b-dependent
conversion of SERMs (4-hydroxytamoxifen, 4-OHT) to acti-
vators of estrogen receptor-a (ERa) also failed to occur in
cells null for eitherMEKK1 or TAB2 (Figures 4B and 4C). Sim-
ilarly, antagonists of progesterone receptor (PR) were also
switched to agonists in response to IL-1b, and both
MEKK1 and TAB2 were required for agonistic actions of
PR antagonists (Figure 4D). In contrast, even in the same
LNCaP cells, retinoic acid receptor-a (RARa)-dependent re-
pression was not altered by IL-1b either in the absence of
ligands or even with binding of the RARa antagonist LG815
(Figure 4E). Moreover, RARa-dependent activation or re-
pression (mediated by N-CoR) was not altered by disrupting
TAB2 or MEKK1 functions using IgGs or dominant negative
mutant counterparts (Figure 4F). ChIP assays revealed that
the N-CoR holocorepressor complex, including TBLR1,
mSin3A/B-containing complexes, and HDAC3, was present
on the RARb promoter (Figure 4G). On this RARa target,
TAB2 recruitment could not be detected in either the pres-
ence or absence of antagonists. This is in contrast to the
presence of TAB2 in the N-CoR holorepressor complex on
the PSA promoter in response to SARMs (Figure 4G and
data not shown).
The receptor specificity of the IL-1b response is consistent
with the hypothesis that IL-1b-dependent dismissal of N-
CoR holocorepressor complexes on AR, ER, and PR re-
quires the presence of a component of the N-CoR complex,
TAB2, that is not successfully recruited to unliganded or to
antagonist bound RXR/RAR complexes, raising the question
of why TAB2 is recruited to some nuclear receptors but not
to others. One striking difference between sex hormone re-
ceptors and retinoic acid and thyroid hormone receptors is
the relative importance of the N terminus in gene activation
events and the presence of distinct activation domains (AF1)
in the N terminus of ER and AR (Alen et al., 1999; Bevan
et al., 1999; Tremblay et al., 1999). Indeed, the N-terminal
domain of ERa is > 180 aa, and that of AR is > 530 aa, com-
pared to a relatively short (<90 aa) RARa N terminus.
We therefore examined the possibility that the N termini
of AR, ER, or PR harbored the key for inclusion of TAB2
into the N-CoR holocorepressor complex. Consistent with
this model, we find that TAB2 can interact with the N ter-
minus of either AR (aa 1–512) or ERa (aa 1-173) in coimmu-
noprecipitation assays (Figure 5A). Further, with removal of
the AR N terminus (aa 2-500), in comparison to androgen
holoreceptor, there was no change in the recruitment of re-
ceptors themselves and other components of the N-CoR
holocomplex, including HDAC3, TBLR1, and mSin3A/B inCell 124, 615–629, February 10, 2006 ª2006 Elsevier Inc. 619
Figure 3. IL-1b Converts AR Antagonists
to Agonists
(A) Pretreatment of cells with IL-1b abolished
CPA or bicalutamide-mediated repression of an
ARE-containing reporter, and microinjection of
CMV-N-CoR expression plasmid restored the
antagonist function.
(B) ChIP assay on the PSA promoter in LNCaP
cells in the presence of CPA and IL-1b. LNCaP
cells were pretreated with CPA for 1 hr, and dis-
missal of the corepressor complex was assessed
at indicated times after IL-1b treatment.
(C) LNCaP cells were maintained in charcoal-
stripped medium and exposed to CPA in the ab-
sence or presence of IL-1b. Cells were stained
with aN-CoR IgG and visualized using deconvo-
lution microscopy. Merged images with nuclear
DAPI staining (blue) are shown.
(D) Microinjection of aTAB2 and aMEKK1 IgGs
into Rat-1 cells with AR and ARE-LacZ reporter
in the presence or absence of DHT or CPA.
(E) A reporter under the control of ARE was mi-
croinjected into either MEKK1/ or wild-type
(wt) MEFs, and the effects of treatment of DHT,
CPA, or IL-1b were tested in the presence of AR.
(F) In TAB2/ MEFs, IL-1b-dependent andro-
gen-like activity of CPA was abolished.
(G) Role of TAB2 in bicalutamide-dependent re-
pression of AR function. Using TAB2/ MEFs,
an AR-dependent reporter gene is not activated
by bicalutamide/IL-1b cotreatment unless wt
TAB2 is expressed or N-CoR/SMRT are depleted
by 48 hr of specific siRNAs.
(H) In MEKK1/ MEFs, bicalutamide acts as an
antagonist upon bicalutamide/IL-1b cotreatment
unless wt MEKK1 or a C478A mutant is added.
Data are represented as mean ± SEM.response to SARMs, but there was a loss of ability to recruit
TAB2 (Figure 5B, and data not shown). A similar result was
found with ERa, wherein the presence of the N terminus
(aa 1-170) is required for recruitment of TAB2 but not for
other components of the N-CoR holocomplex in response
to SERMs (data not shown). Finally, with replacement of (or
addition to) the RARa N terminus (aa 1-60) with that of either
the AR (aa 1-512) or ERa (aa 1-173), the RARa fusion pro-
teins (AR-N’/RAR, ER-N’/RAR) can now exhibit MEKK1-620 Cell 124, 615–629, February 10, 2006 ª2006 Elsevier Inc.and TAB2-dependent activation with RARa antagonist or
in the absence of ligands in response to IL-1b (Figure 5C
and data not shown). Further, a serial two-step ChIP assay
confirmed that N-CoR and TBLR1 components were pres-
ent on both RARa and the AR-N’/RARa fusion receptor
and that TAB2 could be recruited only to the fusion receptor
(Figure 5C and data not shown), suggesting that the steroid
hormone receptor N termini are required for TAB2 recruit-
ment to the N-CoR complex during repression. Retinoic
Figure 4. Steroid Hormone Receptor-
Specific Derepression by IL-1b
(A) Expression-profiling of AR target genes using
Superarray HS-031 in LNCaP cells treated with
DHT, bicalutamide, and bicalutamide/IL-1b. De-
tectable upregulated genes upon normalization
were marked in red. The list of the genes and
quantitative expression levels are shown in Table
S1.
(B) Effects of IL-1b on pS2 promoter-dependent
reporter in wt or TAB2/ MEFs.
(C) The ability of MEKK1 expression vectors to
rescue 4-OHT-mediated activation in response to
IL-1b. Wt MEKK1, C478A MEKK1 (mutant of E3
ligase activity), or D1369A MEKK1 (mutant of ki-
nase activity) was used to rescue IL-1b-depen-
dent activation of the ERE promoter by 4-OHT
in MEFs from MEKK1/ mice.
(D) Effects of progesterone (Prog) and RU486 on
a PRE-dependent reporter in response to IL-1b,
using single-cell nuclear microinjection assays in
wt and MEKK1/ MEFs.
(E) IL-1b fails to activate unliganded or antagonist
(LG815) bound RAR in Rat1 cells.
(F) Antibody against MEKK1 and a dominant-
negative TAB2 (TAB2mut) show no effect on
LG815 or RA actions in response to IL-1b. Data
are represented as mean ± SEM.
(G) Two-step ChIP analysis of RARb and PSA
promoters in LNCaP cells, showing that PSA pro-
moter recruits TBLR1 and TAB2 when cells are
treated with CPA for 1 hr, while RARb promoter
only recruits TBLR1, though not TAB2, in cells
cultured in charcoal-stripped medium.acid stimulated the chimeric RARa, but neither E2 nor DHT
exerted activation effects (Figure 5C and data not shown).
To localize a potential interaction domain(s), HA-NLS-
tagged fragments of ERa N terminus and endogenous
TAB2 were tested by coimmunoprecipitation/Western blotanalysis. These studies revealed that only aa 1-45 of the
ERa N terminus permitted TAB2 binding (Figure 5D). Again,
the initial 45 aa of ERa N terminus was sufficient to cause di-
rect interactions with TAB2 using bacterially expressed ERa
fragments. Further mapping revealed that this interactionCell 124, 615–629, February 10, 2006 ª2006 Elsevier Inc. 621
Figure 5. The Evolutionarily Conserved N-Terminal L/HX7LL Motif of Steroid Hormone Receptors Is Crucial for TAB2 Recruitment
and IL-1b-Induced Derepression
(A) Immunoprecipitation of extracts of 293 cells transfected (or mock-transfected cells as the control) with N terminus of AR (1-512 aa) or ERa (1-173 aa)
(expressed as HA-tagged, NLS-containing fusion proteins) by aHA antibody. Specific TAB2 interaction with AR or ERaN terminus was detected byWestern
blot.
(B) Role of ARN terminus in TAB2 recruitment to SARM-bound AR on target genes (PSA). Expression vectors encoding Flag-tagged full-length AR orDN-AR
(501-919) were transfected into LNCaP cells, and cells were treated with CPA for 1 hr if needed. Then a 2-step ChIP was performed, first using aFlag IgG
and then aTAB2 IgG. Lower panels: CPA-treated or untreated LNCaP cells transfected with AR or DN-AR Flag-tagged vectors were examined by 2-step
ChIP (first aFlag and then acorepressors) on the PSA promoter for binding of N-CoR, HDAC3, and TAB2. Mock-transfected cells were used as the control
for ChIP analysis (upper-right panel). Western blot confirmed equivalent expression of AR and DN-AR (lower-right panel).
(C) Single-cell nuclear microinjection assays on fusion proteins of N terminus of AR (aa 1-512) or ERa (aa 1-173) and DN-RARa (61-462), showing an IL-1b-
induced, MEKK1- and TAB2-dependent activation of an RARa-dependent reporter in the absence of ligand. A 2-step ChIP showed specific cooccupancy
of TAB2 with AR-N’/RARa fusion receptor but not with the wild-type RARa.
(D) Coimmunoprecipitation of endogenous TAB2 with HA-tagged different fragments of ERa N terminus.622 Cell 124, 615–629, February 10, 2006 ª2006 Elsevier Inc.
was dependent upon the C terminus (aa 400-693) of TAB2,
a region that also harbors the critical regulatory MEKK1
phosphorylation site (aa 419-423) and the NES site (aa 547-
561) (Figure 5E). Finally, deletion of aa 1-45 of the ERa
N-terminal sequence within the ERa-N’/RARa chimeric re-
ceptor caused loss of IL-1b response, while deletion of aa
46-90 or aa 91-135 failed to block IL-1b-induced activation
(Figure 5F).
Within the TAB2 regulatory N-terminal sequences of AR
and of ERa, we identified a sequence, L/HXXAXXXXLL (re-
ferred to as L/HX7LL), conserved between species and be-
tween AR, ERa, and PR and also related to a sequence pres-
ent in BCL3 (Figure 5G), which is recruited to the p50 site of
KAI1, a site that also recruits TAB2with the N-CoR holocom-
plex and that is derepressed in response to IL-1b (Baek et al.,
2002). These residues are predicted to form a specific puta-
tive helical structure (Reid et al., 2002). To further test the hy-
pothesis that this site is required or even sufficient to confer
interactions with TAB2 and mediate IL-1b effects, we de-
leted the N-terminal 15 aa, including HX7LL sequence from
the ERa–N’/RARa fusion protein (DHX7LL), finding that dele-
tion of the sequence caused loss of its ability to transfer ac-
tivation of RARa by IL-1b (Figure 5H). Replacement of the
HX7LL sequence of ERa with the corresponding LX7LL se-
quence of AR, though not an AX7AA mutant AR sequence,
was sufficient to restore IL-1b-mediated activation of ERa–
N’/RARa on an RARE or on the RARb promoter (Figure 5H
and data not shown). A mutant (L14,15A) of ERa holorecep-
tor with disrupted HX7LLmotif was found to lose response to
IL-1b in the presence of antagonist, while the agonist-in-
duced activation was fully intact (Figure 5I). As an indepen-
dent confirmation, we transfected 293 cells with the tagged
AR wild-type (LX7LL) or mutant (AX7AA) motif-containing
RARa fusion receptors and tagged wild-type ERa or the
ERa(L14,15A) mutant and performed a coimmunoprecipita-
tion analysis, finding a decreased interaction of the mutant
receptors with TAB2 (Figures S3B and S3C). Therefore,
the ability to recruit TAB2 into the nuclear receptor-recruited
N-CoR holocorepressor complex and to be derepressed by
a proinflammatory cytokine are conferred by a specific, evo-
lutionarily conserved sequence that is present in both AR
and ERa.To test whether competition for TAB2 binding to the L/
HX7LLmotif might actually be sufficient to block IL-1b activa-
tion of androgen target genes by SARMs, we used the sin-
gle-cell nuclear microinjection assay to introduce a 14mer
synthetic peptide encompassing either the AR LX7LL motif
or the same sequence with L/A substitutions (AX7AA)
into cells expressing PSA promoter-dependent reporters.
We found that the AR N-terminal LX7LL peptide specifically
blocked IL-1b-mediated activation function of bicalutamide,
while the mutated AX7AA sequence failed to inhibit induction
(Figure 5J). Moreover, the antagonist/IL-1b-mediated induc-
tion of the endogenous AR gene target PSA was prevented
bymicroinjection of LX7LL but not AX7AApeptide (Figure 5K).
Therefore, this sequence is required and sufficient to medi-
ate TAB2 recruitment and IL-1b-mediated derepression.
To test whether the L/HX7LL motif is also crucial for macro-
phage-induced derepression in prostate cells, we performed
nuclear microinjection of the AR-N’ LX7LL 14mer peptide
into RWPE1 cells pretreated with TNFa to induce VCAM-1
and interaction with THP-1 macrophages as described in
Figure 1. Intriguingly, the LX7LL-containing peptide, though
not the AX7AA mutant, blocked the macrophage-induced
agonistic ‘‘switch’’ of bicalutamide (Figure 5L), implying a po-
tential therapeutic approach to treating hormone resistance
induced by macrophage/cancer cell interaction in prostate
cancer.
We finally explored the mechanisms by which MEKK1 in-
duces TAB2/N-CoR dismissal from the target gene pro-
moters in response to proinflammatory signals via the sug-
gested MEKK1-dependent phosphorylation of TAB2 (Baek
et al., 2002). We performed coimmunoprecipitation of en-
dogenous TAB2, N-CoR, and HA-tagged AR N terminus
(1-512) after overexpression of MEKK1, observing that acti-
vation of MEKK1 kinase activity inhibited TAB2 interactions
with the AR N terminus while enhancing its interactions with
N-CoR, consistent with its function in removal of the N-CoR
holocorepressor complex in derepression (Figure S3D).
Potential Physiological Roles of N-CoR/TAB2-
Dependent Derepression
While these observations have produced initial evidence for
an unexpected mechanism underlying some aspects of(E) GST pull-down assays using different fragments of ERaN terminus fused to GST and in vitro translated full-length, N-terminal (aa 1-399) or C-terminal (aa
400-693) TAB2. The Coomassie blue staining of the purified GST fusion proteins showed similar amounts used in the assays.
(F) Deletion of the 1-45 aa of ERaN terminus, though not other fragments, abrogated the IL-1b -mediated derepression of the ERa-N’/RARa fusion receptor
in the single-cell microinjection assays using an RARa-dependent reporter.
(G) Alignment of L/HX7LL motif in AR, ERa, PR, and Bcl-3 of different species.
(H) Specific deletion and replacement of the L/HX7LL motifs or mutant (AX7AA) of ERa and AR in the ERa-N’/RARa fusion receptor in the single-cell mi-
croinjection assays using an RARa-dependent reporter.
(I) Single-cell microinjection assays using pS2 promoter-controlled reporter and ERa expression plasmids in Hela cells. Mutations of L/HX7LL motif of ERa
(L14,15A) restored 4-OHT-dependent repression in the presence of IL-1b.
(J) In single-cell microinjection assays using PSA promoter-controlled reporter in RWPE1 prostate cells, synthetic 14mer peptide harboring wt LX7LL motif
but not the mutant AX7AA abolished the IL-1b-mediated conversion of antagonist to agonist.
(K) PSA mRNA expression measured by real-time quantitative RT-PCR after single-cell nuclear microinjection of wt LX7LL or mutant AX7AA peptide in
RWPE1 prostate cells. Values are relative ratios to basal expression and normalized to b-actin levels.
(L) Macrophage/prostate cell interaction was set up as described in Figure 1. By single-cell nuclear microinjection, the 14mer wt LX7LL and mutant AX7AA
peptides were coinjected into RWPE1 prostate cells with a reporter driven by the PSA promoter, followed by the addition of ligands to the medium. Data are
represented as mean ± SEM.Cell 124, 615–629, February 10, 2006 ª2006 Elsevier Inc. 623
SARM/SERM resistance in prostate and breast cancers,
they simultaneously raise a perplexing issue. Given the evo-
lutionary conservation of the L/HX7LL motif in specific nu-
clear receptors as well as the MEKK1/TAB2 effectors of
the proinflammatory pathways, it is reasonable to conclude
that there must be a physiologically important function that
underlies this conserved response system. While many pos-
sible scenarios can be imagined, initial data led us to inves-
tigate the putative negative regulation of specific gene ex-
pression by E2. Indeed, a number of genes are reported,
directly or indirectly, to be downregulated by estrogens (Fra-
sor et al., 2003; Cicatiello et al., 2004, Lin et al., 2004). One
such gene that is negatively regulated in response to E2 is
BMP7, and this would be predicted to exert key biological
roles in several tissues. It has been suggested that E2 bound
ERa might be recruited to the BMP7 promoter and inhibit
BMP7 expression by direct mechanisms (Kusumegi et al.,
2004; Lin et al., 2004). In fact, we found that the E2-
dependent repression of BMP7 was relieved in response
to IL-1b, following the same logic as the SARM/SERM dere-
pression pathway (Figure 6A).
To better understand the extent to which the evolutionarily
conserved mechanism that underlies resistance to SARM/
SERM regulates derepression of agonist bound sex steroid
receptors, we compared a genome-wide analysis of pro-
moter occupancy by ERa using a human 20 k array designed
for a new assay of genome-wide location analysis, the ChIP-
DSL-Chip method (I.G.-B., Y.-S. Kwon, M.G.R., X.-D. Fu,
unpublished data), and previous analyses (Laganiere et al.,
2005) to a list of genes reported to be downregulated in
MCF7 cells in response to estrogen. Remarkably, only 17
of these downregulated genes actually exhibit promoter oc-
cupancy by ERa, suggesting that the direct negative regula-
tion by E2 may actually be limited to a rather discrete set of
genes. We therefore tested these candidates and verified
that the transcripts of eight genes, including ABCG2 and
BCL3, were downregulated by E2, while the positive target
pS2 was induced in MCF7 cells (Figure 6A and data not
shown). Importantly, addition of IL-1b reversed E2-depen-
dent repression of these genes (Figure 6A), suggesting that
the macrophage/IL-1b-mediated TAB2 derepression mech-
anism could underlie physiological events. To test the role of
the N-CoR complex in E2-dependent repression, we evalu-
ated the activity of the BMP7 or ABCG2 proximal pro-
moter-controlled luciferase reporter in wt and N-CoR/
MEFs. E2-induced repression of reporters was fully abol-
ished in N-CoR knockout cells, revealing genetically the es-
sential role of N-CoR in this event (Figure 6B). Using the
BMP7-luciferase reporter in 293 cells, we confirmed that in
the presence of ERa, E2 decreased the reporter activity,
whereas combination of E2 and IL-1b restored the reporter
activity to the baseline (Figure 6C). A dominant-negative mu-
tant of TAB2, or TAB2 siRNA, abrogated derepression of the
BMP7 promoter-dependent reporter, suggesting an essen-
tial role of TAB2 in this regulation. In contrast to wild-type
ERa, an ERa construct harboring point mutations (E203A/
G204A) which prevent its DNA binding-dependent activities
but not trans activities (Jakacka et al., 2001) fully abrogated624 Cell 124, 615–629, February 10, 2006 ª2006 Elsevier Inc.the E2-mediated repression of the reporter, suggesting that
the DNA binding ability of ERa is crucial for regulation of
BMP7 expression (Figure 6C). We noted that the promoters
of BMP7, ABCG2, and BCL3 each harbor putative half-ER
binding sites. Consistent with these observations, ChIP anal-
ysis in MCF7 cells revealed that ERa, N-CoR, and TAB2 re-
cruitment were enriched on the gene-regulatory regions of
BMP7, ABCG2, and BCL3 upon E2 treatment and that
N-CoR/TAB2 were released in response to E2/IL-1b, al-
though the relative amount of occupancy varied slightly on
different promoters in response to E2 and IL-1b (Figure 6D).
Quantitative ChIP analysis of BMP7 promoter by real-time
PCR confirmed a robust enrichment of ERa, N-CoR, and
TAB2 triggered by E2 and a complete dismissal of N-CoR
and TAB2 by addition of IL-1b (Figure 6E). These data pro-
vide a physiological explanation for evolutionary conserva-
tion of the N-CoR/TAB2/L/HX7LL-dependent mechanism
that underlies the ‘‘switch’’ of SARM function in response
to IL-1b. This is particularly relevant in light of the fact that
a key aspect of reproductive regulation, blastocyst implanta-
tion, involves a local induction of BMP7 in response to in-
flammatory signals (Monroe et al., 2000; Paria et al., 2001).
The transporter ABCG2 plays a role in the placenta to protect
the developing fetus from xenobiotic stimuli during gestation
(Suzuki et al., 2003), and BCL3 is linked to the regulation of
the p50/52 homodimer-dependent subset of NF-kB targets.
This pathway is, of course, likely to serve other biological
functions, perhaps as a release of inhibition by unliganded
receptor under specific protein kinase regulation, exerting
roles in the immune and reproductive systems.
DISCUSSION
A Macrophage/Prostate Cancer Cell Signaling
Pathway Causes Resistance to SARMs
The studies reported in this manuscript have provided initial
evidence that interactions between macrophages and pros-
tate cancer cells serve to mediate specific aspects of tumor
behavior and responses to AR antagonists based on an evo-
lutionarily conserved sensor system. Thus, in addition to
clear roles of macrophages in atherosclerosis (reviewed in
Li and Glass, 2002), presumptive roles in diabetes mellitus,
and correlation with vascularization of tumors (reviewed in
Coussens and Werb, 2002), macrophages appear capable
of serving as an important aspect of SARM resistance in
prostate cancer. Here we have found that macrophage/
prostate cancer interactions appear almost universal in clin-
ical tumor samples, which could implicate macrophage-
produced cytokines as a virtually ubiquitous signal in dictat-
ing prostate cancer cell responses. These observations are
consistent with reports of monocytic/macrophage infiltration
of prostate and breast cancers, particularly within surround-
ing stroma (Leek et al., 1996; Shimura et al., 2000). Prostate
cancer cells are reported to be capable of producing chemo-
attractants, e.g., GM-CSF, which might be the initial step
for macrophage recruitment (Chung et al., 1999). We have
provided evidence that this macrophage/prostate cancer
cell interaction, ultimately mediated via VCAM-1-dependent
Figure 6. Physiological Roles of Inflammatory Signal-Dependent Derepression in Sex Steroid Receptor Regulation
(A) Semiquantitative RT-PCR analysis of ERa target genes in MCF-7 cells upon different treatments. Actin was used as the loading control.
(B) Reporter assays using luciferase reporters driven by a human BMP7 or ABCG2 promoter sequence (BMP7: 1091 to 250 and ABCG2: 872 to +6;
numbers indicate relative positions to ATG and transcription start site, respectively). Reporter activities were tested in wt or N-CoR/ MEFs by transient
cotransfection with ERa.
(C) BMP7 promoter-controlled luciferase reporter assays. Wt ERa and ERa (E203A/G204A) were cotransfected with reporter in 293 cells. Expression levels
of wt and mutant ERa were similar, and siRNA knock-down of TAB2 was efficient (>70%) (data not shown).
(D) ChIP analysis ofBMP7,ABCG2, andBCL3 promoters. The primer pair marked ‘‘promoter’’ flanks putative ERE half sites, and primer pair ‘‘control’’ flanks
a region 3 kb upstream of BMP7 promoter.
(E) Quantitative ChIP analysis of BMP7 promoter using real-time PCR. Values are relative ratios to corresponding input. Data are represented as mean ±
SEM.
(F) Model of nuclear receptor-specific derepression program in response to proinflammatory signals.Cell 124, 615–629, February 10, 2006 ª2006 Elsevier Inc. 625
adhesion, causes macrophage activation and production of
cytokines, including IL-1b, which are sufficient to cause resis-
tance to antagonists (SARMs). These data suggest that the
interaction between these two cell types serves, at least, as
an important component of the ‘‘resistance’’ events in pros-
tate cancer. This is consistent with the idea that, in addition to
roles in infection and surveillance, the recruitment and activa-
tion of macrophages is probably a key aspect of many dis-
eases. Because we have found that peptides corresponding
to the L/HX7LL motif of AR or ERa can block macrophage-
dependent resistance, we suggest that this peptide inhibitor
may serve as a prototype for identifying antiagonists that
might act to prevent inflammatory cytokine-dependent
switch in SARM or SERM function and hence ‘‘block’’ resis-
tance. Our data would also suggest that IL-1b-
mediated MEKK1 activation is likely to be the major macro-
phage-induced pathway for SARM resistance.
Molecular Mechanism of Proinflammatory Signal-
Induced Derepression of Specific Nuclear Receptors
The macrophage/prostate cancer cell interaction dictates
a coordinated program of transcriptional response to an in-
flammatory cytokine resulting in derepression of a subset
of N-CoR/SMRT-repressed genes based on the presence
or absence of a specific molecular beacon, TAB2, which
acts as a sensor of specific inflammatory signaling pathways.
We find that recruitment of an N-CoR ‘‘holocorepressor’’
complex, including the TBL1/TBLR1-, mSin3-, and Brg1-
containing components that are simultaneously recruited
with N-CoR to AR, and multiple, required HDAC enzymatic
activities serve to maintain repression on SARM bound
AR. However, it is the inclusion of a specific component,
TAB2, that underlies macrophage/prostate cancer cell dere-
pression events. This complexity of the holocorepressor
machinery may serve primarily to permit an ‘‘integration’’ of
transcriptional responses to additional regulatory signals, ex-
emplified by the selective derepression of specific cohorts of
N-CoR-repressed genes in response to proinflammatory
signaling events.
Intriguingly, the molecular basis for recruitment of TAB2 to
the N-CoR holocorepressor complex by AR, ER, and PR
proves to lie in the specific interaction between TAB2 and
an evolutionarily conserved N-terminal ‘‘L/HX7LL’’ sequence
that permits recruitment of TAB2 to the N-CoR holocore-
pressor complex in a receptor/TAB2/N-CoR ternary com-
plex (Figure 5G). This L/HX7LL TAB2 recognition motif can
transfer recruitment of TAB2 and IL-1b-sensitive derepres-
sion to RARa that lacks themotif. In the case of p50 gene tar-
gets, a similar L/HX7LL sequence in BCL3 appears to medi-
ate recruitment of TAB2 (our unpublished data). Therefore,
the genomic response to IL-1b-dependent actions in dere-
pression appears to be determined by a specific motif that
serves to alter the composition of the N-CoR corepressor
complex by recruiting the TAB2 component.
While the cytoplasmic function of TAB2 in IL-1b-induced
activation of NF-kB p50/p65 heterodimers is unimpaired in
TAB2-deficient embryonic fibroblasts, probably due to com-
pensation by the related TAB3 (Sanjo et al., 2003), the626 Cell 124, 615–629, February 10, 2006 ª2006 Elsevier Inc.nuclear function of TAB2 in permitting IL-1b-dependent co-
repressor dissociation based on phosphorylation of TAB2 by
MEKK1 (Baek et al., 2002) is lost in these cells. The potential
conformational change in TAB2 upon phosphorylation
simultaneously weakens its association with the AR/ER N
terminus while enhancing its association with the N-CoR
complex, which probably enables it to mediate dismissal of
the entire N-CoR ‘‘holocorepressor’’ complex. Thus, DNA
binding factor-specific recruitment of certain components
of the corepressor holocomplex can serve as the ‘‘molecular
beacon’’ for integrating nuclear transcriptional responses of
different signaling pathways (Figure 6F), accounting for the
resistance of other nuclear receptors like RARa to IL-1b
signals.
Negative Gene Regulation As the Evolutionary Basis
of the L/HX7LL/TAB2 Mechanism
Based on the data presented here, we are tempted to sug-
gest that this regulatory mechanism selective for sex steroid
receptors arose in the context of gene inhibition by estrogen,
androgen, and/or progesterone agonists. Here, on the pro-
moters of BMP7, ABCG2, and BCL3, E2 causes recruitment
of the ERa/N-CoR/TAB2 complex, and IL-1b reverses this
E2-dependent repression along the N-CoR/TAB2-depen-
dent pathway. In the absence of N-CoR, E2-dependent re-
pression is abolished, and macrophage/IL-1b-induced de-
repression is reversed by inhibition of TAB2. This provides
at least one physiological explanation for this evolutionarily
conserved L/HX7LL-dependent TAB2 recruitment and sug-
gests that this mechanism, which derepresses a subset of
E2-repressed genes in response to inflammatory signals,
may play critical roles in several biological processes, partic-
ularly in reproductive biology. Indeed, macrophages are inti-
mately connected with the development of hormone respon-
sive tissues and reproductive organs (Cohen et al., 1999;
Gouon-Evans et al., 2000). It is intriguing to note that blasto-
cyst implantation into the uterus constitutes an ‘‘inflamma-
tory event’’ with regulated production of cytokines such as
IL-1b and the closely related IL-18 (de los Santos et al.,
1996) by both maternal cells and the blastocyst itself, which
in turn direct remodeling of endometrium at the site of im-
plantation. Strikingly, BMP7 expression is locally induced in
the tissue immediately adjacent to the implanting blastocyst,
exactly at the putative site of IL-1 action in the implantation
process (Paria et al., 2001). Therefore local induction of es-
trogen-inhibited BMP7 levels by inflammatory signals may
facilitate the changes in uterine tissue organization neces-
sary for blastocyst invasion and implantation. The induction
of parturition has recently been proposed to involve acti-
vated, IL-1b-producingmacrophages recruited into the uter-
ine wall in response to signals from the maturing fetus (Con-
don et al., 2004), an event which may also underlie preterm
labor invoked by uterine infection; it is tempting to speculate
similar TAB2/PR-mediated events. The ABCG2 gene en-
codes an ATP binding cassette (ABC) family half-transporter
protein that is highly expressed in the placenta, where it has
been implicated in protecting the developing fetus from xe-
nobiotics during gestation (Suzuki et al., 2003), consistent
with a role in protecting sensitive tissues from cytotoxic, mu-
tagenic, or hormonal stimuli. BCL3 serves as the transacti-
vating component of transcription factor complexes contain-
ing NFkB1/p50 or NFkB2/p52 homodimers, which have
been implicated in the pathogenesis of multiple hormone-
dependent cancers. Thus, it appears reasonable to suggest
that the ability of inflammatory signals to reverse sex hor-
mone-dependent gene repression is an important biological
strategy, related to reproduction and probably other critical
aspects of mammalian homeostasis.
In conclusion, our findings have provided evidence for
a macrophage/prostate cancer regulatory axis that causes
derepression of SARM actions by selective inclusion of TAB2
in the recruited N-CoR holocorepressor complex, and they
exemplify a powerful sensor-based strategy of integrating
genome-wide responses to specific signaling pathways,
apparently of particular physiological relevance in reversing
negative gene regulation events by the sex steroids. Defining
this macrophage/cancer cell functional interaction as a com-
ponent in resistance may provide additional strategies to
modify therapeutic approaches to specific cancers.
EXPERIMENTAL PROCEDURES
Materials and Reagents
The following antibodies were obtained from Santa Cruz Biotechnology:
a-AR, ERa, HDAC1, HDAC2, HDAC3, MBD3, MEKK1, MEK1, BRG1,
and mSin3A/B. See Supplemental Data for all other antibodies and
reagents.
Macrophage Binding Assay
RWPE-1 cells were seeded on glass coverslips at subconfluent density
and subsequently treated with cytokines for 6 hr. THP-1 cells were la-
beled with 30-O-Acetyl-20,70-bis(carboxyethyl)-4 or 5-carboxyfluorescein
diacetoxymethyl ester (BCECF-AM) (Molecular Probes, Inc) following
manufacturer’s instructions. The labeled macrophages were resus-
pended in DMEM and added in a small volume to the RWPE-1 cells
and incubated with gentle agitation for 30 min. Coverslips were washed
with PBS and either mounted for microscopy or quantitatively analyzed
by flourimetry.
Small Interfering RNA
The small interfering RNA (siRNAs) were delivered into cells by single-cell
microinjection or transfection using Lipofectamine 2000 (Invitrogen).
Information of siRNAs is available in Supplemental Data.
Single-Cell Nuclear Microinjection Assays and Luciferase
Reporter Assays
Microinjection assays and Luciferase reporter assays were carried out as
previously described (Kamei et al., 1996; Heinzel et al., 1997). Details are
available in Supplemental Data.
Chromatin Immunoprecipitation Assays
The ChIP assay was conducted as previously described (Shang et al.,
2000; Zhu et al., 2004). Details are described in Supplemental Data.
RNA Profiling
GEArray Q Series Human Androgen Signaling and Prostate Cancer Gene
Array (HS-031, Superarray Bioscience, Frederick, MD) was used to per-
form RNA expression profiling experiments of AR target genes. See Sup-
plemental Data for details.RT-PCR and Real-time Q-PCR
Semi-quantitative RT-PCR was carried out as described (Zhu et al.,
2004). For real-time Q-PCR, standard procedure was followed according
to the Mx3000P Real-Time PCR Systems and the Brilliant QPCR reagent
kits (Stratagene). Details are available in Supplemental Data.
Tissue Microarray and Immunohistochemistry
Prostate tissue microarrays (Cat# A302) were purchased from ISU Abxis
(Seoul, South Korea) and stained as previously described (Zhu et al.,
2004).
All other experimental procedures are available in Supplemental Data.
Supplemental Data
Supplemental Data include three figures, one table, Experimental Proce-
dures, and References and can be found with this article online at http://
www.cell.com/cgi/content/full/124/3/615/DC1/.
ACKNOWLEDGMENTS
We thank A. Aggarwal for advice on structures of protein motifs, M. Karin
for MEKK1 (/) MEFs, T. Hunter for MEKK1 mutants, C. Nelson for
technical assistance, A. Gonzalez (Santa Cruz Biotechnology) for advice
on reagents, and J. Hightower and M. Fisher for figure and manuscript
preparation. P.Z. is supported by a long-term postdoctoral fellowship
from the Human Frontier Science Program (HFSP). S.H.B. is supported
by the SRC/ERC program of MOST/KOSEF and the National R&D pro-
gram for cancer control. M.G.R. is an investigator with the Howard
Hughes Medical Institute. This work was supported by grants from NCI
to M.G.R., NIH to D.W.R., C.K.G., and M.G.R., and the PCRP to M.G.R.
Received: July 22, 2005
Revised: October 26, 2005
Accepted: December 1, 2005
Published: February 9, 2006
REFERENCES
Alen, P., Claessens, F., Verhoeven, G., Rombauts, W., and Peeters, B.
(1999). The androgen receptor amino-terminal domain plays a key role
in p160 coactivator-stimulated gene transcription. Mol. Cell. Biol. 19,
6085–6097.
Alland, L., Muhle, R., Hou, H., Jr., Potes, J., Chin, L., Schreiber-Agus, N.,
and DePinho, R.A. (1997). Role for N-CoR and histone deacetylase in
Sin3-mediated transcriptional repression. Nature 387, 49–55.
Baek, S.H., Ohgi, K.A., Rose, D.W., Koo, E.H., Glass, C.K., and Rose-
nfeld, M.G. (2002). Exchange of N-CoR corepressor and Tip60 coactiva-
tor complexes links gene expression by NF-kB and b-amyloid precursor
protein. Cell 110, 55–67.
Bevan, C.L., Hoare, S., Claessens, F., Heery, D.M., and Parker, M.G.
(1999). The AF1 and AF2 domains of the androgen receptor interact
with distinct regions of SRC1. Mol. Cell. Biol. 19, 8383–8392.
Chen, C.D., Welsbie, D.S., Tran, C., Baek, S.H., Chen, R., Vessella, R.,
Rosenfeld, M.G., and Sawyers, C.L. (2004). Molecular determinants of re-
sistance to antiandrogen therapy. Nat. Med. 10, 33–39.
Chen, J.D., and Evans, R.M. (1995). A transcriptional co-repressor that
interacts with nuclear hormone receptors. Nature 377, 454–457.
Chung, T.D., Yu, J.J., Spiotto, M.T., Bartkowski, M., and Simons, J.W.
(1999). Characterization of the role of IL-6 in the progression of prostate
cancer. Prostate 38, 199–207.
Cicatiello, L., Scafoglio,C., Altucci, L., Cancemi,M.,Natoli,G., Facchiano,
A., Iazzetti, G., Calogero, R., Biglia, N., De Bortoli, M., et al. (2004). A
genomic view of estrogen actions in human breast cancer cells by expres-
sion profiling of the hormone-responsive transcriptome. J. Mol. Endocri-
nol. 32, 719–775.Cell 124, 615–629, February 10, 2006 ª2006 Elsevier Inc. 627
Cleutjens, K.B., van Eekelen, C.C., van der Korput, H.A., Brinkmann,
A.O., and Trapman, J. (1996). Two androgen response regions cooperate
in steroid hormone regulated activity of the prostate-specific antigen pro-
moter. J. Biol. Chem. 271, 6379–6388.
Cohen, P.E., Nishimura, K., Zhu, L., and Pollard, J.W. (1999). Macro-
phages: important accessory cells for reproductive function. J. Leukoc.
Biol. 66, 765–772.
Condon, J.C., Jevasuria, P., Faust, J.M., and Mendelson, C.R. (2004).
Surfactant protein secreted by the maturing mouse fetal lung acts as
a hormone that signals the initiation of parturition. Proc. Natl. Acad. Sci.
USA 101, 4978–4983.
Coussens, L.M., and Werb, Z. (2002). Inflammation and cancer. Nature
420, 860–867.
Darimont, B.D., Wagner, R.L., Apriletti, J.W., Stallcup, M.R., Kushner,
P.J., Baxter, J.D., Fletterick, R.J., and Yamamoto, K.R. (1998). Structure
and specificity of nuclear receptor-coactivator interactions. Genes Dev.
12, 3343–3356.
Debes, J.D., and Tindall, D.J. (2004). Mechanisms of androgen-refractory
prostate cancer. N. Engl. J. Med. 351, 1488–1490.
De los Santos, M.J., Mercader, A., Frances, A., Portoles, E., Remohi, J.,
Pellicer, A., and Simon, C. (1996). Role of endometrial factors in regulating
secretion of components of the immunoreactive human embryonic inter-
leukin-1 system during embryonic development. Biol. Reprod. 54, 563–
574.
Feldman, B.J., and Feldman, D. (2001). The development of androgen-
independent prostate cancer. Nat. Rev. Cancer 1, 34–45.
Frasor, J., Danes, J.M., Komm, B., Chang, K.C., Lyttle, C.R., and Katze-
nellenbogen, B.S. (2003). Profiling of estrogen up- and down-regulated
gene expression in human breast cancer cells: insights into gene net-
works and pathways underlying estrogenic control of proliferation and
cell phenotype. Endocrinology 144, 4562–4574.
Glass, C.K., and Rosenfeld, M.G. (2000). The coregulator exchange in
transcriptional functions of nuclear receptors. Genes Dev. 14, 121–141.
Gouon-Evans, V., Rothenberg, M.E., and Pollard, J.W. (2000). Postnatal
mammary gland development requires macrophages and eosinophils.
Development 127, 2269–2282.
Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z.W., Egan, L.J.,
Kagnoff, M.F., and Karin, M. (2004). IKKb links inflammation and tumor-
igenesis in a mouse model of colitis-associated cancer. Cell 118, 285–
296.
Guenther, M.G., Lane, W.S., Fischle, W., Verdin, E., Lazar, M.A., and
Shiekhattar, R. (2000). A core SMRT corepressor complex containing
HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes
Dev. 4, 1048–1057.
Heinzel, T., Lavinsky, R.M., Mullen, T.M., Soderstrom, M., Laherty, C.D.,
Torchia, J., Yang, W.M., Brard, G., Ngo, S.D., Davie, J.R., et al. (1997). A
complex containing N-CoR, mSin3 and histone deacetylase mediates
transcriptional repression. Nature 387, 43–48.
Ho¨rlein, A.J., Naar, A.M., Heinzel, T., Torchia, J., Gloss, B., Kurokawa, R.,
Ryan, A., Kamei, Y., Soderstrom, M., Glass, C.K., and Rosenfeld, M.G.
(1995). Ligand-independent repression by the thyroid hormone receptor
mediated by a nuclear receptor co-repressor. Nature 377, 397–404.
Hu, X., and Lazar, M.A. (1999). The CoRNRmotif controls the recruitment
of corepressors by nuclear hormone receptors. Nature 402, 93–96.
Jackson, T.A., Richer, J.K., Bain, D.L., Takimoto, G.S., Tung, L., and
Horwitz, K.B. (1997). The partial agonist activity of antagonist-occupied
steroid receptors is controlled by a novel hinge domain-binding coactiva-
tor L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol. 11,
693–705.
Jakacka, M., Ito, M., Weiss, J., Chien, P.Y., Gehm, B.D., and Jameson,
J.L. (2001). Estrogen receptor binding to DNA is not required for its activity
through the nonclassical AP1 pathway. J. Biol. Chem. 276, 13615–
13621.628 Cell 124, 615–629, February 10, 2006 ª2006 Elsevier Inc.Jepsen, K., and Rosenfeld, M.G. (2002). Biological roles and mechanistic
actions of co-repressor complexes. J. Cell Sci. 115, 689–698.
Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin,
S.C., Heyman, R.A., Rose, D.W., Glass, C.K., and Rosenfeld, M.G.
(1996). A CBP integrator complex mediates transcriptional activation
and AP-1 inhibition by nuclear receptors. Cell 85, 403–414.
Kim, J.H., Kim, B., Cai, L., Choi, H.J., Ohgi, K.A., Tran, C., Chen, C.,
Chung, C.H., Huber, O., Rose, D.W., et al. (2005). Transcriptional regu-
lation of a metastasis suppressor gene by Tip60 and beta-catenin com-
plexes. Nature 434, 921–926.
Kusumegi, T., Tanaka, J., Kawano, M., Yonemoto, J., Tohyama, C., and
Sone, H. (2004). BMP7/ActRIIB regulates estrogen-dependent apopto-
sis: new biomarkers for environmental estrogens. J. Biochem. Mol. Tox-
icol. 18, 1–11.
Laganiere, J., Deblois, G., Lefebvre, C., Bataille, A.R., Robert, F., and
Giguere, V. (2005). Location analysis of estrogen receptor alpha target
promoters reveals that FOXA1 defines a domain of the estrogen re-
sponse. Proc. Natl. Acad. Sci. USA 102, 11651–11656.
Lavinsky, R.M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T.M., Schiff,
R., Del-Rio, A.L., Ricote, M., Ngo, S., Gemsch, J., et al. (1998). Diverse
signaling pathways modulate nuclear receptor recruitment of N-CoR
and SMRT complexes. Proc. Natl. Acad. Sci. USA 95, 2920–2925.
Leek, R.D., Lewis, C.E., Whitehouse, R., Greenall, M., Clarke, J., and
Harris, A.L. (1996). Association of macrophage infiltration with angiogen-
esis and prognosis in invasive breast carcinoma. Cancer Res. 56, 4625–
4629.
Li, A.C., and Glass, C.K. (2002). The macrophage foam cell as a target for
therapeutic intervention. Nat. Med. 8, 1235–1242.
Li, J., Wang, J., Wang, J., Nawaz, Z., Liu, J.M., Qin, J., and Wong, J.
(2000). Both corepressor proteins SMRT and N-CoR exist in large protein
complexes containing HDAC3. EMBO J. 19, 4342–4350.
Lin, C.Y., Strom, A., Vega, V.B., Kong, S.L., Yeo, A.L., Thomsen, J.S.,
Chan, W.C., Doray, B., Bangarusamy, D.K., Ramasamy, A., et al.
(2004). Discovery of estrogen receptor alpha target genes and response
elements in breast tumor cells. Genome Biol. 5, R66.
Lu, Z., Xu, S., Joazeiro, C., Cobb, M.H., and Hunter, T. (2002). The PHD
domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitina-
tion and degradation of ERK1/2. Mol. Cell 9, 945–956.
McKenna, N.J., and O’Malley, B.W. (2002). Combinatorial control of gene
expression by nuclear receptors and coregulators. Cell 108, 465–474.
Monroe, D.G., Jin, D.F., and Sanders, M.M. (2000). Estrogen opposes
the apoptotic effects of bone morphogenetic protein 7 on tissue remod-
eling. Mol. Cell. Biol. 20, 4626–4634.
Nagy, L., Kao, H.Y., Chakravarti, D., Lin, R.J., Hassig, C.A., Ayer, D.E.,
Schreiber, S.L., and Evans, R.M. (1997). Nuclear receptor repression me-
diated by a complex containing SMRT, mSin3A, and histone deacetylase.
Cell 89, 373–380.
Nagy, L., Kao, H.Y., Love, J.D., Li, C., Banayo, E., Gooch, J.T., Krishna,
V., Chatterjee, K., Evans, R.M., and Schwabe, J.W.R. (1999). Mechanism
of corepressor binding and release from nuclear hormone receptors.
Genes Dev. 13, 3209–3216.
Nolte, R.T., Wisely, G.B., Westin, S., Cobb, J.E., Lambert, M.H.,
Kurokawa, R., Rosenfeld, M.G., Willson, T.M., Glass, C.K., and Milburn,
M.V. (1998). Ligand binding and co-activator assembly of the peroxisome
proliferator-activated receptor-g. Nature 395, 137–143.
Onate, S.A., Boonyaratanakornkit, V., Spencer, T.E., Tsai, S.Y., Tsai,
M.J., Edwards, D.P., and O’Malley, B.W. (1998). The steroid receptor co-
activator-1 contains multiple receptor interacting and activation domains
that cooperatively enhance the activation function 1 (AF1) and AF2 do-
mains of steroid receptors. J. Biol. Chem. 273, 12101–12108.
Paria, B.C., Ma, W., Tan, J., Raja, S., Das, S.K., Dey, S.K., and Hogan,
B.L. (2001). Cellular and molecular responses of the uterus to embryo
implantation can be elicited by locally applied growth factors. Proc. Natl.
Acad. Sci. USA 98, 1047–1052.
Perissi, V., Staszewski, L.M., McInerney, E.M., Kurokawa, R., Krones, A.,
Rose, D.W., Lambert, M.H., Milburn, M.V., Glass, C.K., and Rosenfeld,
M.G. (1999). Molecular determinants of nuclear receptor-corepressor in-
teraction. Genes Dev. 13, 3198–3208.
Perissi, V., Aggarwal, A., Glass, C.K., Rose, D.W., and Rosenfeld, M.G.
(2004). A corepressor/coactivator exchange complex required for tran-
scriptional activation by nuclear receptors and other regulated transcrip-
tion factors. Cell 116, 511–526.
Reid, J., Kelly, S.M., Watt, K., Price, N.C., and McEwan, I.J. (2002). Con-
formational analysis of the androgen receptor amino-terminal domain in-
volved in transactivation. Influence of structure-stabilizing solutes and
protein-protein interactions. J. Biol. Chem. 277, 20079–20086.
Sande, S., and Privalsky, M.L. (1996). Identification of TRACs (T3 recep-
tor-associating cofactors), a family of cofactors that associate with, and
modulate the activity of, nuclear hormone receptors. Mol. Endocrinol.
10, 813–825.
Sanjo, H., Takeda, K., Tsujimura, T., Ninomiya-Tsuji, J., Matsumoto, K.,
and Akira, S. (2003). TAB2 is essential for prevention of apoptosis in fetal
liver but not for interleukin-1 signaling. Mol. Cell. Biol. 23, 1231–1238.
Shang, Y., Hu, X., DiRenzo, J., Lazar, M.A., and Brown, M. (2000). Cofac-
tor dynamics and sufficiency in estrogen receptor-regulated transcription.
Cell 103, 843–852.
Shang, Y., Myers, M., and Brown, M. (2002). Formation of the androgen
receptor transcription complex. Mol. Cell 9, 601–610.
Shiau, A.K., Barstad, D., Loria, P.M., Cheng, L., Kushner, P.J., Agard,
D.A., and Greene, G.L. (1998). The structural basis of estrogen recep-
tor/coactivator recognition and the antagonism of this interaction by ta-
moxifen. Cell 95, 927–937.
Shimura, S., Yang, G., Ebara, S., Wheeler, T.M., Frolov, A., and Thomp-
son, T.C. (2000). Reduced infiltration of tumor-associated macrophages
in human prostate cancer: association with cancer progression. Cancer
Res. 60, 5857–5861.
Smith, C.L., Nawaz, Z., and O’Malley, B.W. (1997). Coactivator and co-
repressor regulation of the agonist/antagonist activity of the mixed anties-
trogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11, 657–666.Suzuki, M., Suzuki, H., Sugimoto, Y., and Sugiyama, Y. (2003). ABCG2
transports sulfated conjugates of steroids and xenobiotics. J. Biol.
Chem. 278, 22644–22649.
Takaesu, G., Kishida, S., Hiyama, A., Yamaguchi, K., Shibuya, H., Irie, K.,
Ninomiya-Tsuji, J., andMatsumoto, K. (2000). TAB2, a novel adaptor pro-
tein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in
the IL-1 signal transduction pathway. Mol. Cell 5, 649–658.
Tremblay, A., Tremblay, G.B., Labrie, F., and Giguere, V. (1999). Ligand-
independent recruitment of SRC-1 to estrogen receptor beta through
phosphorylation of activation function AF-1. Mol. Cell 3, 513–519.
Underhill, C., Qutob, M.S., Yee, S.P., and Torchia, J. (2000). A novel nu-
clear receptor corepressor complex, N-CoR, contains components of the
mammalian SWI/SNF complex and the corepressor KAP-1. J. Biol.
Chem. 275, 40463–40470.
Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L.,
and Ferrante, A.W., Jr. (2003). Obesity is associated with macrophage
accumulation in adipose tissue. J. Clin. Invest. 112, 1796–1808.
Wen, Y.-D., Perissi, V., Staszewski, L.M., Yang,W.-M., Krones, A., Glass,
C.K., Rosenfeld, M.G., and Seto, E. (2000). The histone deacetylase-3
complex contains nuclear receptor corepressors. Proc. Natl. Acad. Sci.
USA 97, 7202–7207.
Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J.,
Nichols, A., Ross, J.S., Tartaglia, L.A., and Chen, H. (2003). Chronic in-
flammation in fat plays a crucial role in the development of obesity-related
insulin resistance. J. Clin. Invest. 112, 1821–1830.
Yoon, H.G., Chan, D.W., Huang, Z.Q., Li, J., Fondell, J.D., Qin, J., and
Wong, J. (2003). Purification and functional characterization of the human
N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J. 22,
1336–1346.
Zhang, J., Kalkum, M., Chait, B.T., and Roeder, R.G. (2002). The N-CoR-
HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway
through the integral subunit GPS2. Mol. Cell 9, 611–623.
Zhang, Y., Ng, H.H., Erdjument-Bromage, H., Tempst, P., Bird, A., and
Reinberg, D. (1999). Analysis of the NuRD subunits reveals a histone de-
acetylase core complex and a connection with DNA methylation. Genes
Dev. 13, 1924–1935.
Zhu, P., Martin, E., Mengwasser, J., Schlag, P., Janssen, K.P., and
Gottlicher, M. (2004). Induction of HDAC2 expression upon loss of
APC in colorectal tumorigenesis. Cancer Cell 5, 455–463.Cell 124, 615–629, February 10, 2006 ª2006 Elsevier Inc. 629
